- CLINICAL PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
American Board of Internal Medicine
MD, Jefferson Medical College
Residency, Internal Medicine
University of Michigan Hospitals
Harvard Medical School
Brigham and Women's Hospital
Dr. Elliot Rayfield is a Clinical Professor of Medicine (Endocrinology, Diabetes, and Bone Diseases). Dr. Rayfield is Board Certified in Endcrinology and Metabolism. His practice is centered on Types 1 and 2 Diabetes and Clinical Endocrinology. Dr. Rayfield serves as Chair of the Development Committee of the Endocrine Society and is on the Editorial Board of Endocrine Practice. Dr. Rayfield is a Fellow of the American College of Clinical Endocrinology and a member of the American Diabetes Association.
The Jacobi Medallion
Mount Sinai Alumni Association
First Professional Education Service Award
American Diabetes Association, Downstate Affiliate, New York
Fifth Annual Distinguished Research Award, Department of Medicine
Mount Sinai Medical Center
1975 - 1980
NIH Research Career Development Award
National Institutes of Health
1975 - 1976
American Diabetes Association Research and Development Award
Mount Sinai Medical Center
Alpha Omega Alpha
Jefferson Medical College
LeRoith D, Rayfield E. The benefits of tight glycemic control in type 2 diabetes mellitus. Clinical Cornerstone 2007; 8(Suppl. 7): S19-S29.
Potenza M, Rayfield E. Targeting the Incretin System in Type 2 Diabetes. Mount Sinai Journal of Medicine 2009;.
Rayfield E. Evidence-Based Medicine-A Brief Review. Insulin 2010; 5: 7-10.
Magnotti M, Rayfield E. The HumaPenR Luxura TM HD Pen-- What Is the Role of 0.5-Unit Insulin Dosing? . Journal of Diabetes Science and Technology 2010 March; 4.
Rayfield E. Evidence-Based Medicine-GAPPNETTM and its Role in Patient Care. Insulin 2010; 5: 74-76.
Rayfield E. Clark T Sawin Library and Resource Center: An Update. Endocrine News 2010 September;.
Farkouh M, Rayfield E, Fuster V. Diabetes and Cardiovascular Disease. In: The Heart (Thirteenth Edition). pp2028-2058.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Rayfield is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
1150 Park Avenue
New York, NY 10128
- Monday 8:00am - 3:00pm
- Tuesday 10:00am - 3:00pm
- Wednesday 8:00am - 3:00pm
- Thursday 10:00am - 3:00pm
- Friday 8:00am - 3:00pm
- Aetna U.S. Healthcare
- CIGNA - Indemnity
- Empire Blue Cross/Blue Shield
- Medicare Assignment
- Metrahealth/United Health
- Oxford Health Plans
- United Healthcare